{"timeline":{"headline":"Cytokines and Chemokines in Erythema Migrans","type":"default","text":"History of NCT02147249","startDate":"2014,05,23","date": [{"startDate":"2014,05,23","headline":"View of NCT02147249 on 2014_05_23","text":"<table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT02147249</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2014_05_23</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Cytokines and Chemokines in Erythema Migrans</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>N/A</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Basic Science</td>\n</tr>\n<tr>\n<th>Study design</th><td>Open Label</td>\n</tr>\n<tr>\n<th>Study design</th><td>Single Group Assignment</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: inflammatory proteins in erythema migrans patients<br/>Time Frame: up to 12 months follow-up<br/>Safety Issue? No<br/>Description: <p>The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses in serum and if available, skin, of patients during active infection and after treatment.</p>\n</td>\n</tr>\n<tr>\n<th>Secondary outcome</th><td>Measure: gene polymorphisms in erythema migrans patients<br/>Time Frame: at enrollment<br/>Safety Issue? No<br/>Description: <p>The expression of disease-relevant genomic variants will be assessed using ImmunoChip.</p>\n</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Erythema Migrans\n      </td>\n</tr>\n<tr>\n<th>Arm/Group</th><td>\n<div>Arm Label: erythema migrans patients treated with antibiotics      \n            \u00a0 \u00a0 \u00a0 \u00a0\n        Experimental</div>\n<p>adult patients with erythema migrans will be treated with oral antibiotics</p>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: antibiotic treatment\n            \u00a0 \u00a0 \u00a0 \u00a0\n            Arm Label: erythema migrans patients treated with antibiotics</div>\n<p>Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days<br/>or cefuroxime axetil orally, 500 mg, bid, 14 days<br/>or amoxicillin orally, 500 mg, tid, 14 days</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>Recruiting</td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         2013-07\n      </td>\n</tr>\n<tr>\n<th>Primary completion date</th><td>\n         2015-12\n      \n      (Anticipated)\n  </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Inclusion Criteria:<br/> \u00a0- erythema migrans in patients &gt; 18 years<br/>\n<br/>Exclusion Criteria:<br/>\n<br/> \u00a0\u00a0- pregnancy or lactation<br/> \u00a0\u00a0- taking antibiotic with antiborrelial activity within 10 days</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>18 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>University Medical Centre Ljubljana</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>EM-0613</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               University Medical Centre Ljubljana\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               University of Ljubljana School of Medicine,  Slovenia\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Medical University of Vienna\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Harvard University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               Slovenia: Ethics Committee\n         </td>\n</tr>\n</table>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}}]}}